Abstract:Louis Chhor, 1, 2 Stefan Saggese, 2 Garun S Hamilton, 1, 3 Martin Ian MacDonald 1 1 Monash Lung, Sleep, Allergy & Immunology, Monash Health, Melbourne, Victoria, Australia; 2 Department of General Medicine, Monash Health, Melbourne, Victoria, Australia; 3 School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia Correspondence: Louis Chhor, Department of General Medicine, Dandenong Hospital, 135 David St, Dandenong, VIC, 3175, Australia, Tel +61 3 9544 1000, Email Objective: To compare clinical characteristics and outcomes of hospitalized acute exacerbations of COPD (AECOPD)s secondary to SARS-CoV-2 versus other respiratory viruses amongst a highly vaccinated population in the Omicron era. Design: Retrospective cohort study; analysis of hospital medical records and linked pathology and radiology reports. Setting: Tertiary health network in Victoria, Australia; January 2022–August 2022. Main Outcome Measures: Key clinical information including comorbidities, vaccination status, treatments administered and outcomes such as hospital length of stay, ICU admission, non-invasive ventilation usage and inpatient mortality. Results: One hundred ninety-nine viral AECOPDs - 125 SARS-CoV-2 and 74 other viruses were identified. Of the SARS-CoV-2 group. 13.6% were unvaccinated, 17.6% partially and 68.0% fully vaccinated. The SARS-CoV-2 group were older (77.2 vs 68.9, p < 0.00001) with more comorbidities (1[1– 2] vs 1[0– 2], p = 0.008) and lower candidacy for full resuscitation (25.6% vs 56.8%, p < 0.0001). Mortality tended to be higher among SARS-CoV2 admission (9.6% v 2.7%, p = 0.066) but rates of ICU admission (10.4% v 13.5%, p = 0.507), length of hospitalisation (5[3– 8] vs 5[3– 9], p = 0.9) and readmission within 30 days (25% vs 33.3%, p = 0.184) were similar. Conclusion: In a highly vaccinated population in the Omicron era, COPD patients requiring hospitalisation with SARS-CoV-2 are older with more comorbidities than those admitted with other respiratory viruses. Length of hospitalisation and ICU utilisation was similar. Inpatient mortality may be higher. Keywords: SARS-CoV2, coronavirus, COPD, viral exacerbations Patients with chronic obstructive pulmonary disease (COPD) are vulnerable to severe acute exacerbations (AECOPDs) when they contract respiratory viruses. 1 Exacerbations of COPD are cardinal events in the disease, associated with accelerated decline in lung function, reduced quality of life, hospitalization and mortality. 2–4 Viral infection appears to be responsible for up to 50% of AECOPDs. 5,6 The prognosis of virus-associated exacerbation appears different to other exacerbation etiotypes, with a slower recovery and prolonged hospitalization. 7,8 In general, studies examining hospitalized AECOPDs have considered all respiratory viruses as a generic grouping, with outcomes compared between "viral" and "non-viral" exacerbations or versus alternative broad etiologies such as bacterial or eosinophilic exacerbations. 9–11 Studies of individual viruses such as rhinovirus ("common cold"), influenza and Respiratory Syncytial Virus (RSV) have been performed, although there are very limited data to indicate whether specific respiratory viruses have different impacts as causes of severe AECOPDs. The relative impact of SARS-CoV-2 versus previously circulating respiratory viruses as a cause of severe AECOPD has been little studied. One prospective observational cohort study in the United Kingdom compared outcomes from AECOPDs secondary to SARS-CoV-2 versus groups with either alternative infections (bacterial or viral), or non-infective AECOPDs. 10 They reported higher 30-day mortality, longer hospital stays and more frequent requirement for positive pressure ventilatory support among the SARS-CoV-2 group. Much of this data was collected during the early phases of the pandemic with circulating wild-type, alpha and delta strains. Since the onset of the COVID pandemic, widespread vaccination and development of effective therapeutics have been achieved, limiting applicability of early pandemic data to the current era. SARS-CoV-2 is now an endemic community respiratory virus, and it is therefore necessary to evaluate the clinical phenotype of AECOPD secondary to SARS-CoV-2 contextualized alongside other commonly circulating respiratory viruses. We hypothesized that sub-populations of COPD patients may be more vulnerable when hospitalized with AECOPD due to SARS-CoV-2 compared to other respiratory viruses, which may inform and guide clinical management, prevention strategies and prognosis. We therefore analyzed hospi -Abstract Truncated-

Antibiotic Prescriptions in Hospitalized Patients with an Exacerbation COPD and a Proven Influenza or RS Virus Infection

In-hospital antibiotic use for severe chronic obstructive pulmonary disease exacerbations: a retrospective observational study

The use of antibiotics in the early stage of acute exacerbation of chronic obstructive pulmonary disease in patients without obvious signs of infection: a multicenter, randomized, parallel-controlled study

Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons

A Survey of Antibiotic Usage Characteristics in Treatment of Acute Exacerbation of COPD Patients in National Hospital 74

Nebulization of Antimicrobial Agents in Mechanically Ventilated Adults in 2017: an International Cross-Sectional Survey

Association of Antibiotic Treatment With Outcomes in Patients Hospitalized for an Asthma Exacerbation Treated With Systemic Corticosteroids

Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice.

Antibiotic Overuse in Pediatric Patients Hospitalized with RSV, COVID-19, and Influenza

Antimicrobial therapies for prevention of recurrent acute exacerbations of COPD (AECOPD): beyond the guidelines

Influenza and pneumococcal vaccination coverage and associated factors in patients hospitalized with acute exacerbations of COPD in China: Findings from the real-world data

Real-world antibiotic use in treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China: Evidence from the ACURE study

Clinical Characteristics and Outcomes of Hospitalized AECOPDs Secondary to SARS-CoV-2 versus Other Respiratory Viruses

Clinical practice of respiratory virus diagnostics in critically ill patients with a suspected pneumonia: A prospective observational study

A Systematic Review of the Pulmonary Microbiome in Patients with Acute Exacerbation COPD Requiring ICU Admission

Differences in antibiotic use between COPD and non-COPD residents based on the health information system

Characterization of respiratory bacterial co-infection and assessment of empirical antibiotic treatment in patients with COVID-19 at hospital admission

Antibiotic use during influenza infection augments lung eosinophils that impair immunity against secondary bacterial pneumonia

The Current Status of Vaccine Uptake and the Impact of COVID-19 on Intention to Vaccination in Patients with COPD in Beijing

Hospitalised exacerbations of chronic obstructive pulmonary disease: adherence to guideline recommendations in an Australian teaching hospital

Respiratory Infection Triggering Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease